Mark Sullivan
InvestorVenture Partner at Adjuvant Capital
Melbourne, Australia
Writes $100K – $5M checks · typically $1.5M
About
Mark Sullivan has 11 years of executive management, advisory, and board experience in biotechnology, along with 28 years in clinical development spanning biotech, large pharmaceutical, contract services, and academic settings. He has led project development of five biopharmaceutical products, the most recent of which received FDA approval in June 2018. At GHIF he led the team that brought the moxidectin program through late-stage development to FDA approval as a new treatment for onchocerciasis.
Invests in
Biotech
Colleagues at Adjuvant Capital
Abrar Haque
Associate at Adjuvant Capital
Alexandra (Sandra) Glucksmann
Advisory Partner at Adjuvant Capital
Christian Mandl
Senior Advisor at Adjuvant Capital
Curt LaBelle
Venture Partner at Adjuvant Capital
David Washer
Investor at Adjuvant Capital
Evelyn Yanatos
Director of Finance and Compliance at Adjuvant Capital
Gerard Cunningham
Operating Partner at Adjuvant Capital
Giulia Balconi
Associate at Adjuvant Capital
Network1
Investors connected to Mark in public investor directories — a warm-intro map.